INT101697

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.16
First Reported 2002
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 4
Total Number 4
Disease Relevance 0.55
Pain Relevance 1.42

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
Notch 1
vasculature 1
CPA 1
Ang2 (Mus musculus)
Pain Link Frequency Relevance Heat
Antinociceptive 14 99.98 Very High Very High Very High
adenocard 12 98.68 Very High Very High Very High
agonist 8 97.80 Very High Very High Very High
antinociception 2 93.64 High High
antagonist 10 92.80 High High
Inflammation 7 50.00 Quite Low
withdrawal 5 33.84 Quite Low
cINOD 19 5.00 Very Low Very Low Very Low
COX-2 inhibitor 3 5.00 Very Low Very Low Very Low
Perioperative pain 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Colon Cancer 7 86.16 High High
Targeted Disruption 17 80.96 Quite High
Intestinal Cancer 3 77.36 Quite High
Cancer 69 68.96 Quite High
Breast Cancer 50 50.00 Quite Low
Vibrio Infection 23 50.00 Quite Low
INFLAMMATION 11 50.00 Quite Low
Sprains And Strains 4 32.60 Quite Low
Disease 8 30.80 Quite Low
Carcinoma 1 27.68 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
These data indicate that the antinociceptive effect of Ang II interacts with that produced by adenosine A1 receptor agonist.
Negative_regulation (effect) of Ang II associated with adenocard, agonist and antinociceptive
1) Confidence 0.16 Published 2002 Journal Pharmacol. Biochem. Behav. Section Abstract Doc Link 11900765 Disease Relevance 0 Pain Relevance 0.73
Ang II (0.1 microg/mouse) administered 5 min before CPA (0.25 mg/kg) decreased the number of writhes, i.e., it enhanced the antinociceptive effect of CPA.
Negative_regulation (decreased) of Ang II in CPA associated with antinociceptive
2) Confidence 0.16 Published 2002 Journal Pharmacol. Biochem. Behav. Section Abstract Doc Link 11900765 Disease Relevance 0 Pain Relevance 0.69
Consistent with the marked reduction in mammary vasculature in Cox-2 null mammary tissues, the expression of several angiogenesis-associated genes was decreased (Figure 5b), including VEGF (which encodes vascular endothelial growth factor), Ang1 and Ang2 (which encode Tie-2 ligands), and Flk-1 and Flt-1 (which encode vascular endothelial growth factor receptors).
Negative_regulation (decreased) of Ang2 in vasculature
3) Confidence 0.14 Published 2007 Journal Breast Cancer Res Section Body Doc Link PMC2206709 Disease Relevance 0.55 Pain Relevance 0
This combined treatment (CT) contains the Tie2 ligand Ang2, the Notch ligand Dll4, a JAK kinase inhibitor, and insulin.
Negative_regulation (inhibitor) of Ang2 in Notch
4) Confidence 0.14 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2877108 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox